



Proteomic Phenotyping of Stimulated Müller Cells Uncovers Profound Pro-Inflammatory Signaling and Antigen-Presenting Capacity

Adrian Schmalen^{1,2}, Lea Lorenz², Antje Grosche³, Diana Pauly^{4,5}, Cornelia A. Deeg^{2*} and Stefanie M. Hauck^{1*}

OPEN ACCESS

Edited by:

Settimio Rossi,
Second University of Naples, Italy

Reviewed by:

Karen Eastlake,
University College London,
United Kingdom
Sandra M. Cardona,
University of Texas at San Antonio,
United States
Ana Isabel Arroba,
Fundación Para la Gestión de la
Investigación Biomédica de
CádizCádiz, Spain

*Correspondence:

Cornelia A. Deeg
deeg@tiph.vetmed.uni-
muenchen.de
Stefanie M. Hauck
hauck@helmholtz-muenchen.de

Specialty section:

This article was submitted to
Inflammation Pharmacology,
a section of the journal
Frontiers in Pharmacology

Received: 06 September 2021

Accepted: 12 October 2021

Published: 29 October 2021

Citation:

Schmalen A, Lorenz L, Grosche A,
Pauly D, Deeg CA and Hauck SM
(2021) Proteomic Phenotyping of
Stimulated Müller Cells Uncovers
Profound Pro-Inflammatory Signaling
and Antigen-Presenting Capacity.
Front. Pharmacol. 12:771571.
doi: 10.3389/fphar.2021.771571

¹Research Unit Protein Science and Metabolomics and Proteomics Core, Helmholtz Center Munich, German Research Center for Environmental Health (GmbH), Neuherberg, Germany, ²Chair of Physiology, Department of Veterinary Sciences, LMU Munich, Martinsried, Germany, ³Department of Physiological Genomics, Biomedical Center, LMU Munich, Martinsried, Germany, ⁴Experimental Ophthalmology, Philipps-University Marburg, Marburg, Germany, ⁵Department of Ophthalmology, University Hospital Regensburg, Regensburg, Germany

Müller cells are the main macroglial cells of the retina exerting a wealth of functions to maintain retinal homeostasis. Upon pathological changes in the retina, they become gliotic with both protective and detrimental consequences. Accumulating data also provide evidence for a pivotal role of Müller cells in the pathogenesis of diabetic retinopathy (DR). While microglial cells, the resident immune cells of the retina are considered as main players in inflammatory processes associated with DR, the implication of activated Müller cells in chronic retinal inflammation remains to be elucidated. In order to assess the signaling capacity of Müller cells and their role in retinal inflammation, we performed in-depth proteomic analysis of Müller cell proteomes and secretomes after stimulation with INF γ , TNF α , IL-4, IL-6, IL-10, VEGF, TGF β 1, TGF β 2 and TGF β 3. We used both, primary porcine Müller cells and the human Müller cell line MIO-M1 for our hypothesis generating approach. Our results point towards an intense signaling capacity of Müller cells, which reacted in a highly discriminating manner upon treatment with different cytokines. Stimulation of Müller cells resulted in a primarily pro-inflammatory phenotype with secretion of cytokines and components of the complement system. Furthermore, we observed evidence for mitochondrial dysfunction, implying oxidative stress after treatment with the various cytokines. Finally, both MIO-M1 cells and primary porcine Müller cells showed several characteristics of atypical antigen-presenting cells, as they are capable of inducing MHC class I and MHC class II with co-stimulatory molecules. In line with this, they express proteins associated with formation and maturation of phagosomes. Thus, our findings underline the importance of Müller cell signaling in the inflamed retina, indicating an active role in chronic retinal inflammation.

Keywords: Müller cells, atypical antigen-presenting cell, immune response, diabetic retinopathy, oxidative phosphorylation, complement system, cytokines, retina

INTRODUCTION

Neurodegenerative diseases of the retina are characterized by progressive retinal damage eventually resulting in vision loss (Duncan et al., 2018). Accumulating evidence over the last years led to the recognition of chronic inflammation as an important part of the pathogenesis underlying this heterogeneous group of retinal diseases (Wooff et al., 2019; Forrester et al., 2020; Olivares-González et al., 2021). While the loss of photoreceptors in inherited retinal diseases such as retinitis pigmentosa originates in various genetic mutations (Broadgate et al., 2017), the driving force that leads to retinal degeneration and blindness in diabetic retinopathy (DR) is a disturbed metabolism with hyperglycemia and dyslipidemia, resulting in microvascular damage (Lechner et al., 2017). DR is among the most frequent causes of blindness worldwide with a rising prevalence (GBaVI, 2021). Chronic hyperglycemia in diabetes patients induces the activation of leukocytes in the periphery (Chen et al., 2019) as well as micro- and macroglial cells in the retina (Mizutani et al., 1998; Gerhardinger et al., 2005; Zeng et al., 2008). This results in the release of pro-inflammatory cytokines and eventually leads to photoreceptor cell death (Coughlin et al., 2017; Kinuthia et al., 2020). Microglial cells, the resident immune cells of the retina, are acknowledged as the main drivers of retinal immune responses (Karlstetter et al., 2015). However, growing evidence suggests that the interaction of micro- and macroglial cells essentially shapes retinal inflammation and photoreceptor degeneration (Wang et al., 2011; Di Pierdomenico et al., 2020).

Retinal Müller glial cells constitute the primary macroglial cells of the retina (Reichenbach and Bringmann, 2020). They span the entire width of the retina and are in close contact with the vitreous, the retinal blood-vessels and with all retinal neurons (Newman and Reichenbach, 1996). While they maintain retinal homeostasis during steady-state conditions, activation of Müller cells under pathological conditions results in gliosis, a cellular attempt to restore insulted tissue, with both protective and detrimental effects (Bringmann et al., 2006). It is known that Müller cells are an important source of neurotrophic factors but also of pro-inflammatory and angiogenic cytokines (Bringmann et al., 2009; Ruzafa et al., 2018; von Toerne et al., 2014; Hauck et al., 2007). They play an important role in DR pathogenesis (Subirada et al., 2018; Ghaseminejad et al., 2020) and it was also suggested that they are involved in retinal immune responses (Roberge et al., 1988; Rutar et al., 2015; Natoli et al., 2017; Lorenz et al., 2021a; Lorenz et al., 2021b). However, the impact of their protective or detrimental effects on retinal inflammation in DR and other neurodegenerative retinal diseases remains elusive so far. Thus, we performed an in-depth-analysis of the Müller cell proteome and secretome after stimulation with various pro- and anti-inflammatory cytokines as well as growth factors. For our analysis, we used cells of the human Müller glia cell-line MIO-M1 as well as primary porcine retinal Müller Glia (pRMG), as porcine eyes resemble human eyes regarding their anatomy (Middleton S. Porcine ophthalmology, 2010). Furthermore, the pig is established as a useful model for research in diabetic retinopathy (Kleinwort et al., 2017; Renner

et al., 2020). Comparative quantitative proteomic analysis allows to elucidate key proteins or pathways involved in disease pathogenesis. In addition, this approach enables the discovery of new biomarkers and has therefore proven as a valuable tool for deciphering pathophysiological key mechanisms (Konigsberg et al., 2021; Weigand et al., 2021). Our hypothesis-generating study yielded comprehensive data on the capacity of Müller cells to react in a very differentiated manner to varying stimulants. In addition to the secretion of pro-inflammatory cytokines, we observed expression of MHC class I and II molecules and proteins that are associated with the processing of antigens. We therefore propose that Müller cells are critical modulators of the retinal immune response and might exert an antigen-presenting function. Thus, attention should be paid to their implication in chronic inflammation underlying degenerative retinal diseases.

MATERIALS AND METHODS

Cell Preparation and Culture

Cells were maintained in Dulbecco's modified eagle medium (DMEM) containing 10% (v/v) inactivated fetal calf serum (FCS), 100 U/ml penicillin and 100 µg/ml streptomycin unless otherwise stated. Cell culture media and reagents were purchased from Gibco (Life Technologies GmbH, Darmstadt, Germany).

Ten porcine eyes from healthy pigs were kindly provided from a local abattoir. The use of porcine material from the abattoir was approved for purposes of scientific research by the appropriate board of the veterinary inspection office, Munich, Germany (registration number DE 09 162 0008-21). No experimental animals were involved in this study. Within 2 h after enucleation, eyes were processed under a laminar flow hood under sterile conditions as previously described (Lorenz et al., 2021b; Sagmeister et al., 2021). In short, periocular tissue was removed and the eyeballs were rinsed in 80% ethanol followed by washing with cold PBS. Afterwards, eyeballs were stored in DMEM until further processing. The eyeballs were opened circumferentially parallel to the limbus corneae, and anterior parts of the eyes were discarded. The retina was detached from the posterior eyeballs and transferred into a petri dish containing DMEM. After removal of vitreous and pigment epithelium residues, major blood-vessels were excised and the remaining retinal tissue was cut into very small fragments using micro-scissors. Resulting fragments were washed in Ringer's solution followed by enzymatic digestion at 37°C with papain previously activated by incubation with 1.1 mM EDTA, 0.067 mM mercaptoethanol and 5.5 mM cysteine-HCl. Enzymatic digestion was stopped after 12 min by adding serum-containing DMEM, followed by addition of Desoxyribonuclease I (Sigma-Aldrich Chemie GmbH, Taufkirchen, Germany) and trituration. After sedimentation of the cells, the supernatant was carefully removed using Pasteur pipettes. The remaining pellets were resuspended in DMEM, pooled and seeded into 6-well plates (Sarstedt, Nümbrecht, Germany). The following day, thorough panning of the plates and removal of the supernatant were performed in order to

eliminate non-attached cells, yielding pure Müller cell cultures as previously described (Hauck et al., 2003; Eberhardt et al., 2012). Cells were cultured at 37°C and 5% CO₂ with regular exchange of medium and repeated microscopic control of cell density and purity according to previous reports (Limb et al., 2002; Eberhardt et al., 2012).

The human Müller cell line Moorfields/Institute of Ophthalmology-Müller 1 (MIO-M1; RRID:CVCL_0433) was a kind gift of G. A. Limb (Limb et al., 2002). They were tested negative for *mycoplasma* contamination. Two days before treatment, 1×10^5 MIO-M1 cells per well were seeded in 6-well plates and incubated at 37°C and 5% CO₂ until further processing.

Cell Stimulation

The human cytokines Interleukin 10 (IL-10), Transforming Growth Factor beta-1 (TGFβ₁), Transforming Growth Factor beta-2 (TGFβ₂), Transforming Growth Factor beta-3 (TGFβ₃), and Tumor Necrosis Factor Alpha (TNFα) were purchased from Sigma-Aldrich, Interleukin 4 (IL-4) and Interferon Gamma (IFNγ) from R&D Systems/Bio-Techne (R&D Systems/Bio-Techne, Wiesbaden-Nordenstadt, Germany), and Interleukin 6 (IL-6) and Vascular Endothelial Growth Factor165 (VEGF) from PeproTech (PeproTech, Winterhude, Germany). Porcine TGFβ₃ was purchased from Biozol (Biozol, Eching, Germany), whereas porcine TGFβ₁, TGFβ₂, IL-4, IL-6, IL-10, IFNγ and TNFα were from R&D System/Bio-Techne. Since there was no porcine VEGF available, the above mentioned human VEGF was also used for stimulation of pRMG.

To diminish the influence of cytokines present in FCS, both confluent pRMG and MIO-M1 cells were rinsed two times with prewarmed serum-free medium, followed by starvation for 1 h at 37°C and 5% CO₂ with serum-deprived medium. Afterwards, cells were treated over night with IFNγ, IL-4, IL-6, IL-10, TGFβ₁, TGFβ₂, TGFβ₃, TNFα or VEGF165, respectively, in a randomized plate design at a concentration of 5 ng/ml in 2 ml medium without FCS. Untreated cells cultured in serum-free medium served as a control. For this study, cells were treated with each cytokine separately, but not with multiple cytokines in combination.

Sample Collection and Proteolysis

Supernatants were collected 24 h after treatment, passed through medium equilibrated 0.2 μm Millex-GP filter units (Merck Chemicals GmbH, Darmstadt, Germany), and transferred into 2 ml Lo-Bind tubes (Eppendorf AG, Hamburg, Germany). Afterwards, cells were washed once with DPBS. 200 μl RIPA buffer containing Roche cOmplete Mini Protease Inhibitor Cocktail (Merck Chemicals GmbH) was applied directly into each well and cells were detached with a cell scraper. Cell supernatants for the secretome analysis and lysates for the proteome analysis were derived from the same experimental set. Lysates were transferred into freshly prepared 1.5 ml Lo-Bind tubes (Eppendorf AG). Protein concentration of the lysates was determined by Pierce BCA assay (Thermo Fisher Scientific). Ten μg protein per lysate or 400 μl supernatant per sample were digested with Lys-C and trypsin using a modified FASP


procedure as described elsewhere (Wiśniewski et al., 2009; Grosche et al., 2016).

LC-MS/MS and Quantitative Analysis

LC-MSMS analysis was performed on a QExactive HF mass spectrometer (Thermo Fisher Scientific) online coupled to a Ultimate 3000 RSLC nano-HPLC (Dionex, Sunnyvale, United States). Samples were automatically injected and loaded onto a C18 trap column for 5 min. Afterwards, samples were eluted and separated on a C18 analytical column (Acquity UPLC M-Class HSS T3 Column, 1.8 μm, 75 μm × 250 mm; Waters, Milford, United States). Samples were separated by a 95 min non-linear acetonitrile gradient at a flow rate of 250 nl/min. Resolution of the MS spectra was recorded at 60,000 with an AGC target of 3×10^6 and a maximum injection time of 50 ms from 300 to 1,500 m/z. The 10 most abundant peptide ions were selected from the MS scan and fragmented via HCD. Thereby, the normalized collision energy was 27 with an isolation window of 1.6 m/z, and a dynamic exclusion of 30 s. MS/MS spectra were recorded at a resolution of 15,000 with an AGC target of 105 and a maximum injection time of 50 ms. Spectra with unassigned charges, and charges of +1 and >8 were excluded from the precursor selection.

The four datasets (lysates of pRMG and MIO-M1 cells, and secretomes of pRMG and MIO-M1 cells) were analyzed separately. The Proteome Discoverer 2.4 SP1 software (version 2.4.1.15; Thermo Fisher Scientific) was used for peptide and protein identification via a database search (Sequest HT search engine) against the SwissProt Human (MIO-M1) and Ensembl Pig (pRMG). Database search was performed with full tryptic specificity, allowing for up to one missed tryptic cleavage site, a precursor mass tolerance of 10 ppm, and fragment mass tolerance of 0.02 Da. Carbamidomethylation of Cys was set as a static modification. Dynamic modifications included deamidation of Asn and Gln, oxidation of Met, and a combination of Met loss with acetylation on protein N-terminus. Peptide spectrum matches and peptides were validated with the Percolator algorithm (Käll et al., 2007). Each dataset was measured as triplicate. One control sample in the dataset of MIO-M1 secretomes had an unexpected low overall abundance and was excluded as an outlier. Only the top-scoring hits for each spectrum were accepted with a false discovery rate (FDR) < 1% (high confidence). The final list of proteins satisfying the strict parsimony principle included only protein groups passing an additional protein confidence filter FDR < 5% filter (target/decoy concatenated search validation).

Quantification of proteins, after precursor recalibration, was based on intensity values (at RT apex) for all unique peptides per protein. Peptide abundances were normalized to the total peptide amount. The protein abundances were calculated summing the normalized abundance values of corresponding unique peptides. These protein abundances were used for calculation of enrichment ratios of proteins in the stimulated samples to the untreated samples, resulting in single ratios for every quantified protein in every treated sample. Significance of the ratios was tested using a background-based *t*-test with correction for multiple testing according to Benjamini-Hochberg (adjusted *p*-value) (Benjamini et al., 2001; Navarro et al., 2014).



Data Analysis and Visualization

Calculation of the abundance ratio weight requires abundance values for both, the stimulated sample and the control. However, if a protein is exclusively expressed in one of these samples, the Proteome Discoverer software fails to calculate a respective abundance ratio weight. Since these extreme values were of special interest to us, the missing abundance ratio weights were imputed using the R package mice (version 3.13.0) and the “classification and regression trees” imputation method.

Ingenuity Pathway Analysis (IPA; Qiagen, Hilden, Germany) was used to analyze overrepresentation of proteins in canonical pathways of the IPA library, as described elsewhere (Krämer et al., 2014). IPA allows deducing potential physiological effects of the various separately tested cytokines. Analysis was performed based on the fold-change of the stimulated samples and the abundance ratio p -value. Fisher’s exact test allowed testing for nonrandom associations of proteins in the datasets and the different canonical pathways (Fisher, 1922). Furthermore, the method of Benjamini-Hochberg (B-H p -value) corrected for multiple testing (Benjamini et al., 2001).

The euclidean distance for the heatmap analysis was calculated with the open source software Cluster 3.0 and hierarchically clustered by complete linkage clustering (Eisen et al., 1998). The resulting heat map was visualized with the open source software Java Treeview (version 1.2.0) (Saldanha, 2004).

RESULTS

Differential Secretion of Proteins After Stimulation of Müller Cells with Various Cytokines

Müller cells are in close contact to all retinal cells, the vitreous and the blood vessels (Reichenbach and Bringmann, 2020). To address, whether this privileged position within the retina also translates into extensive signaling between Müller cells and the surrounding cells, the secretomes of the human Müller cell-derived cell line MIO-M1 and of pRMG were quantitatively analyzed by mass spectrometry after stimulation for 24 h with the cytokines IFN γ , IL-10, IL-4, IL-6, TGF β 1, TGF β 2, TGF β 3,

TNF α and VEGF, respectively. By this means, we quantified 2,031 proteins in the supernatant of MIO-M1 cells (**Supplementary Table S1**) and 3,093 proteins in the supernatant of pRMG across all treatment groups (**Supplementary Table S2**).

Figure 1 and **Supplementary Figure S1** summarize changes in the secretome after treatment of Müller cells with the different cytokines. A log₂ fold change of ± 0.58 and a corrected *p*-value of equal or less than 0.05 served as cutoff to define significantly upregulated or downregulated genes, respectively. Proteins equally regulated in MIO-M1 cells and pRMG were labeled with their gene symbol. However, this was only possible for proteins with identical gene symbols in the human and the porcine protein database. After treatment with IFN γ , 107 proteins in the secretome of MIO-M1 cells and 176 proteins in the secretome of pRMG were significantly more abundant, while 67 proteins of MIO-M1 cells and 96 proteins of pRMG were significantly less abundant in the supernatants (**Figure 1A**; **Supplementary Figure S1A**). Intriguingly, MIO-M1 cells and pRMG shared 21 upregulated and one downregulated protein. Among these shared regulated proteins after treatment with IFN γ were many with immune system functions, like signaling molecules (e.g., C-X-C Motif Chemokine Ligand 9 (CXCL9), CXCL10, IL-6) and components of the complement system (e.g., C1r, Serpin Family G Member 1 (SERPING1)). Upon treatment with TNF α , 127 (MIO-M1) or 143 (pRMG) proteins were more abundant and 57 (MIO-M1) or 87 (pRMG) proteins were less abundant in the supernatant (**Figure 1B**; **Supplementary Figure S1B**). Within these groups, MIO-M1 cells and pRMG shared 20 upregulated and three downregulated proteins, again with many pro-inflammatory proteins like C-X3-C Motif Chemokine Ligand 1 (CX3CL1), CXCL10, C-C Motif Chemokine Ligand 2 (CCL2), IL-6, and C1r being upregulated. Thus, IFN γ and TNF α resulted in the most conserved changes of the secretome of Müller cells when comparing between stimulated MIO-M1 cells and pRMG. In contrast, MIO-M1 cells and pRMG only shared ten proteins that were more abundant and three which were less abundant after treatment with VEGF, with seven proteins being keratins (**Figure 1C**; **Supplementary Figure S1C**). Treatment of Müller cells with the three different interleukins had a subtle influence on secreted proteins with conserved regulation of seven (IL-4), nine (IL-6), and two (IL-10) proteins in the secretome of MIO-M1 cells and pRMG (**Figures 1D–F**; **Supplementary Figures S1D–F**).


Finally, TGF β s led to pronounced alterations in the secretome of MIO-M1 cells. TGF β 1 enhanced the secretion of 125 proteins while simultaneously reducing the abundance of 67 proteins, TGF β 2 increased the abundance of 131 proteins while impairing secretion of 69 proteins, and TGF β 3 raised abundance of 135 proteins and reduced the abundance of 76 proteins (**Figures 1G–I**). Furthermore, eleven proteins of MIO-M1 cells and pRMG were similarly regulated by TGF β 1, eight upregulated and three downregulated (**Supplementary Figure S1G**). After treatment with TGF β 2, three proteins were more abundant and four proteins less abundant in the secretome of both cell types (**Supplementary Figure S1H**). Additionally, the secretome of TGF β 3 treated MIO-M1 cells and pRMG shared one downregulated protein and eight upregulated proteins, with

most proteins like Osteonectin (Secreted Protein Acidic And Rich In Cysteine; SPARC), Matrix Metalloproteinase 1 (MMP1), Biglycan (BGN) and various keratins being functionally related to extracellular matrix organization (**Supplementary Figure S1I**). Furthermore, stimulation with TGF β 3 evoked upregulation of pro-inflammatory cytokine IFN γ in both, the MIO-M1 cell line and pRMG. Overall, there are subtle, but intriguing differences in protein abundances after stimulation of Müller cells with the different TGF β isoforms. Some of the proteins differentially induced by the TGF β isoforms in MIO-M1 cells are pro-inflammatory cytokines, like IFN γ , TNF α , and CCL2 (**Supplementary Table S1**).

Next, we aimed to examine the physiological functions of proteins secreted by Müller cells. Therefore, we ordered secreted proteins in distinct clusters, grouped by similar expression patterns. From the identified proteins of the MIO-M1 supernatant, all cytosolic contaminants were removed, resulting in a list that exclusively contained extracellular proteins. Furthermore, only those proteins that showed a significant change of abundance (corrected *p*-value ≤ 0.05 and ± 1.5 -fold abundance) in at least one treatment were selected for further analysis. As a result, a hierarchical heat map and an associated dendrogram consisting of 171 proteins was generated using the log₂ abundance ratio of treated and untreated control cells (**Supplementary Figure S2**). Furthermore, clusters were highlighted depending on their position on the dendrogram (**Figure 2**). To avoid single protein clusters, the proteins Polymeric Immunoglobulin Receptor (PIGR) and Lacritin (LACRT) were assigned to Cluster F, despite being on different branches of the dendrogram.

Notably, we identified proteins which were secreted by MIO-M1 cells exclusively after stimulation (cluster A), while another set of proteins was completely absent in MIO-M1 cells (cluster B) treated with VEGF. The largest cluster comprises proteins upregulated by at least one cytokine (cluster C). In contrast to cluster D, consisting of proteins downregulated by TGF β s, TGF β s induce secretion of proteins of cluster E. Finally, secretion of most proteins of cluster F is deterred by at least one cytokine.


The clusters A, C and E are large clusters with proteins upregulated by at least one cytokine, with cluster A being the cluster with the most pronounced changes in secretion of its members and cluster C being the most diffuse one. In order to deduce the physiological functions of the secreted proteins of each of these clusters, we performed gene ontology (GO) analysis. Thereby, redundant pathways were condensed to a single representative pathway and the top 10 pathways with the lowest enrichment FDR were displayed. Intriguingly, the top 10 pathways for cluster A were related to immune system processes, with “Humoral immune response” and “Immune system process” being the most significant pathways with an enrichment FDR of 3.6×10^{-9} and 6.9×10^{-9} , respectively (**Figure 3A**). Furthermore, cluster C contained the pathway “Immune system process”, while most other pathways in this cluster C were involved in shaping the extracellular environment (**Figure 3B**). Besides further pathways involved in extracellular remodeling, the proteins of cluster E were also associated to the pathway “AGE-RAGE signaling pathway in diabetic complications” (**Figure 3C**).



In-Depth Analysis of the Müller Cell Proteome After Stimulation With a Selection of Cytokines

Our secretome analysis hints towards extensive signaling between Müller cells and their cellular environment, differentially induced

upon treatment of Müller cells with various cytokines separately. To elucidate the underlying cellular alterations, we also investigated differences in the proteome of MIO-M1 cells and pRMG cells by mass spectrometry after treatment with these cytokines for 24 h. In total, 5,514 proteins were quantified in the lysates of MIO-M1 cells (**Supplementary Table S3**) and 4,187



proteins in the lysates of pRMG cells (**Supplementary Table S4**) across all treatment groups.

The threshold for significant abundance changes was set using the same cutoff values as for the secretome, and equally regulated proteins in MIO-M1 cells and pRMG were labeled with their gene symbol, if they shared the same gene symbol in the human and the porcine database (**Figure 4; Supplementary Figure S3**). Although the porcine protein database contains mostly humanized gene symbols, the swine leukocyte antigens (SLA) genes show little sequence homology between the human and the porcine genome and cannot properly be humanized (Lunney

et al., 2009). However, Human Leukocyte Antigen-C Alpha Chain (HLA-C) was part of the porcine protein database.

Treatment of Müller cells with IFN γ resulted in 206 more abundant and 88 less abundant proteins in MIO-M1 cells and 331 more abundant and 36 less abundant proteins in pRMG lysates (**Figure 4A; Supplementary Figure S3A**). Thereof, 29 proteins showed higher expression levels in both cells types. Among the overlapping proteins were restriction factors like SAM And HD Domain Containing Deoxynucleoside Triphosphate Triphosphohydrolase 1 (SAMHD1) and MX Dynamin Like GTPase 1 (MX1), transcription factors like Signal Transducer



FIGURE 5 | A comparative IPA analysis with the significantly regulated proteins identified in the pRMG lysates after stimulation with the indicated cytokines was performed. Canonical pathways related to signaling, cell death, immune system processes and oxidative stress were selected. Pathways with significant enrichment of genes after stimulation with at least one cytokine are presented. Significance of the gene enrichment for each pathway and treatment is indicated by purple squares in the left array. Thereby, treatments that did not meet the significance threshold (p -value ≤ 0.05) are marked with a dot. The z-score is indicated in the right array and represents a prediction of activation (orange) or inhibition (blue) of the pathway. Gray squares mark treatments where the activation state of a pathway could not be calculated.

Insulin Like Growth Factor Binding Protein 7 (IGFBP7), JunB Proto-Oncogene (JUNB), and 2-Hydroxyacyl-CoA Lyase 1 (HACL1) were more abundant in both, MIO-M1 cells and pRMG after treatment with TGF β 1. Following treatment with TGF β 2, 125 proteins of the proteome of MIO-M1 cells and 266

proteins of the proteome of pRMG were more abundant, whereas 67 proteins of the MIO-M1 proteome and 229 proteins of the pRMG proteome were less abundantly expressed (**Figure 4H**; **Supplementary Figure S3H**). In the case of treatment with TGF β 3, 130 proteins in the MIO-M1 proteome and 185 in the

pRMG proteome showed higher abundances, while 94 proteins in MIO-M1 proteome and 250 in the pRMG proteome were less abundant (**Figure 4I**; **Supplementary Figure S3I**). The overlap of MIO-M1 cells and pRMG treated with TGF β 2 comprised three proteins, and treatment with TGF β 3 resulted in an overlap of seven proteins. Overall, pRMG reacted more pronounced to treatment with the various cytokines compared to MIO-M1 cells.

Canonical Pathways Enriched in Müller Cells Upon Stimulation

Treatment with cytokines partly induced pronounced changes in the secretome and proteome of Müller cells. In the secretome, these changes primarily included the secretion of pro-inflammatory cytokines and proteins associated with organization of the extracellular matrix. To elucidate overrepresented mechanisms and pathways in stimulated Müller cells, we performed Ingenuity pathway analysis (IPA). We limited the IPA to significantly regulated proteins (p -value ≤ 0.05) identified in the MIO-M1 and pRMG lysates. Since IPA cannot handle porcine gene symbols, we replaced the only canonical SLA gene SLA-1 in our pRMG dataset by the canonical human HLA gene HLA-A. Hence, an IPA core analysis was performed with 1,543 proteins for pRMG and with 2,262 proteins for the MIO-M1 cells. IPA identified 338 canonical pathways within the proteome of MIO-M1 cells and 218 canonical pathways in the proteome of pRMG that were significantly enriched by at least one of the used cytokines (IPA p -value ≤ 0.05 ; **Supplementary Table S5**). Among the identified canonical pathways were many pathways associated with signaling, cell death, immune system processes and the cellular redox state (**Figure 5**; **Supplementary Figure S4**). A selection of canonical pathways enriched in pRMG cells after treatment with at least one of the tested cytokines is depicted in **Figure 5**. All presented pathways in **Figure 5** were also significantly enriched in MIO-M1 cells upon stimulation with at least one cytokine (**Supplementary Figure S4**).


Among the most significantly regulated pathways in MIO-M1 cells and pRMG were the canonical pathways “Mitochondrial Dysfunction” and “Oxidative Phosphorylation”. These pathways were significantly induced by all examined cytokines in pRMG. The pathways “Ferroptosis Signaling Pathway”, “iNOS Signaling”, “NRF2-mediated Oxidative Stress Response”, and “Production of Nitric Oxide and Reactive Oxygen Species in Macrophages” are closely linked to the cellular redox state and were among the enriched pathways in MIO-M1 cells and pRMG after treatment with various cytokines separately. Furthermore, proteins associated with the maturation of phagosomes were significantly enriched in pRMG. In line with this, “Caveolar-mediated Endocytosis Signaling” was significantly enriched in pRMG after treatment with IFN γ , TGF β 1, TNF α and VEGF, and “Clathrin-mediated Endocytosis Signaling” was significantly enriched in pRMG after treatment with all cytokines except IL-10. Besides these two pathways associated with the recycling of the extracellular environment, intracellular protein homeostasis and MHC class I peptide generation was facilitated by enrichment of the “Protein Ubiquitination Pathway” in pRMG after treatment with IFN γ , TGF β 3, TNF α and VEGF. Similarly,

IFN γ , IL-4, TGF β 1, TGF β 3, TNF α and VEGF enriched “Protein Ubiquitination Signaling” in MIO-M1 cells. “Neuroinflammation Signaling” was induced by IFN γ , TNF α and VEGF in MIO-M1 cells and by IFN γ , TGF β 1, TGF β 3 and TNF α in pRMG, whereas TGF β 2 and VEGF led to a slight inhibition of this pathway in pRMG.

A Deeper Look Into Müller Cell Complement Secretion Upon Cytokine Stimulation

Because the enrichment analysis of the secretome yielded highly significant hits such as “humoral immune response” and “immune system process,” we took a closer look at complement proteins in the secretome and cell lysates. Notably, most complement proteins are secreted as key components of the humoral immune system. The identified complement components include central complement proteins, regulators, and receptors. Consistent with their localization in the cell membrane, the latter (including ITGAM, ITGB2, C5aR1) were detected only in cell lysates, and here specifically in those of pRMGs. The complement regulators clusterin (CLU), vitronectin (VTN), CD59, and SERPING were found in most test samples. With regard to the central complement components, the pRMG secretome took a prominent position and showed results for complement components for all three different activation pathways (e.g., C1q, FD, MASP1) and the terminal pathway (e.g., C9). The central complement protein C3 was found in both the MIO-M1 and pRMG secretomes and in the MIO-M1 lysate. Interestingly, cytokine treatment induced changes in complement proteins and regulators but had no effect on complement receptor expression. We observed that C1q subunits, which initiate the classical complement pathway by binding to antibodies, were detectable only in pRMG but not in MIO-M1 cells. C1q levels in cell lysates and the corresponding secretome were consistently reduced after TNF α treatment but were increased by IFN γ . Moreover, complement proteases C1r and C1s, which bind to C1q therewith continuing the cascade of classical pathway activation, were enriched in the supernatants of MIO-M1 and pRMG cells treated with IFN γ (**Figure 2C**). In contrast, C1r concentration was significantly decrease in supernatants of MIO-M1 cells but not pRMG after VEGF and TGF β 2 application. Notably, C1s and C1r were not detected in cellular lysates. Interestingly, the abundance of the central complement proteins C3 and C4a were modified by the supplemented cytokines in MIO-M1 secretomes only and not in any other data set (**Figure 2C**). These proteins are cleaved upon complement activation as for example triggered by the C1q-mediated classical pathway and result in cleaved products which interact with cellular receptors (e.g., C3a/C3b, C4a). Here, complement protein C3 is mainly increased following TNF α addition and C4 upon exposure to IFN γ (**Figure 2C**). In fact, IFN γ was also the major player modulating the secreted complement components in pRMG: C2 and FI were significantly increased while C9, FD and MASP1 were clearly reduced in its presence. These complement components absent from any other sample.

Regarding the complement regulators factor H (FH), SERPING and CLU are of interest. Secretion of FH was not



observed in untreated MIO-M1 and pRMG, but it was significantly upregulated in MIO-M1 secretomes following IFN γ , TNF α , TGF β 3, and VEGF treatment (Figure 2A). Similar results were obtained for SERPING, whose levels were increased by IFN γ in the MIO-M1 secretome, pRMG cell lysates and secretome. Remarkably, the MIO-M1 lysate showed decreased values for CLU following IFN γ , TGF β 1 and TNF α , and similar but not significant trends was observed for the respective secretome. Finally, while CLU was upregulated in pRMGs lysates upon IL-6 or VEGF treatment, no significant alterations could be found in corresponding secretomes.

In summary, IFN γ and TNF α seemed to be the most effective cytokines to modulate the Müller cell complement expression and secretion (Figure 2).


Müller Cells as Atypical Antigen-Presenting Cells

Intriguingly, treatment of pRMG with IFN γ , TGF β 2, TGF β 3 and TNF α significantly enriched proteins associated with the

“Antigen Presentation Pathway”. Likewise, the “Antigen Presentation Pathway” was induced in MIO-M1 cells by treatment with IFN γ , TGF β 1, TNF α and VEGF. Thereby, antigen presentation is an umbrella term for two distinct processes. MHC class I antigen presentation is common to all nucleated cells and allows CD8⁺ cytotoxic T cells (CTL) to assess whether cells are infected with an intracellular pathogen (Hewitt, 2003; Sigal, 2016). In contrast, MHC class II is presented to antigen specific CD4⁺ T cells mainly by professional antigen-presenting cells inducing their activation and differentiation to T helper cells (Roche and Furuta, 2015).

To investigate the antigen presentation capacity of Müller cells, we constructed a hierarchical heatmap for MIO-M1 cells (Figure 6A) and pRMG (Figure 6B) challenged with various cytokines separately. Proteins linked to antigen presentation were selected and clustered hierarchically. Proteins associated with MHC class I antigen presentation are displayed in the upper panel and proteins correlated to MHC class II antigen presentation are depicted in the lower panel. In MIO-M1 cells, IFN γ induced the majority of proteins linked to both, MHC class I and II antigen presentation, whereas TNF α exerted its inductive effect exclusively on MHC class I antigen presentation. The only protein linked to MHC class II antigen presentation induced by TNF α in MIO-M1 cells was Cathepsin S (CTSS). Furthermore, the other cytokines did not induce proteins related to antigen presentation in MIO-M1 cells. Quite the contrary, TGF β 2 and TGF β 3 reduced the abundance of proteins linked to MHC class I antigen presentation in these cells. In contrast to MIO-M1 cells, pRMG reacted to all tested cytokines by induction of components of both MHC class I and II antigen presentation to varying degrees. IFN γ and TNF α induced proteins of MHC class I and II antigen presentation in pRMG, among others SLA-DQA1, SLA-DQB1, SLA-DRA and SLA-DRB1. Furthermore, class I and II antigen presentation was upregulated by TGF β isoforms 1–3 in pRMG. While TGF β 2 and TGF β 3 induced the components of the MHC class I peptide loading complex TAP2 and TAPBP, TGF β 1 also increased the abundance of HLA-DMA and HLA-DMB, proteins involved in the peptide loading on MHC class II. We saw only a subtle induction of proteins related to antigen presentation by IL-10, IL-4 and IL-6. The smallest impact on antigen presentation proteins was seen after stimulation with IL-6. Furthermore, IFN γ significantly upregulated the expression of the co-stimulatory molecule CD40 in pRMG, while TGF β 2, TGF β 3, TNF α and VEGF resulted in lower abundance of CD40 (Supplementary Table S4).

Induction of the canonical MHC class I and MHC class II antigen presentation pathway as assessed by IPA for pRMG after treatment with IFN γ is summarized in Figure 7. This pathway was enriched in pRMG cells with a p -value of 4.15×10^{-12} . Besides MHC class I and MHC class II, also components of the peptide loading complex of MHC class I (TAP2 and TPN) were upregulated in pRMG after IFN γ treatment. Furthermore, IFN γ induces the Large Multifunctional Peptidase 2 (LMP2; synonymous to PSMB9) and Large Multifunctional Peptidase 7 (LMP7; synonymous to PSMB8) subunits of the immunoproteasome in MIO-M1 cells.



DISCUSSION

While microglial cells are considered as the main drivers of retinal immune responses (Karlstetter et al., 2015), increasing evidence suggests that excessive signaling between Müller cells and microglia also affects the inflammatory processes (Wang et al., 2011; Di Pierdomenico et al., 2020). In DR, a condition associated with microvascular degeneration, resulting in ocular inflammation and eventually in complete blindness (Lechner et al., 2017), the production of cytokines by Müller cells plays an essential role for disease pathogenesis, with both beneficial and detrimental effects (Coughlin et al., 2017). We show here that stimulation of Müller cells with pro-inflammatory cytokines like IFN γ or TNF α , but also with growth factors like TGF β or VEGF resulted in profound, yet distinct response profiles in their secretomes, thus confirming their central role in cell-to-cell communication within the retina. In line with this, Müller cells have previously been shown to be an important source of

retinal cytokines (Yoshida et al., 2001; Eastlake et al., 2016). Since the reported physiological concentrations of the tested cytokines is highly variable depending on the analyzed compartment or the method used for quantification, we decided to treat the cells with 5 ng/ml which is in the range of a previous *in vitro* cytokine study with human Müller cells (Yoshida et al., 2001). Furthermore, Yoshida and colleagues showed that the effect of IL-1 on human Müller cells is most pronounced after 24 h of treatment (Yoshida et al., 2001). However, different concentrations or treatment periods might affect the responses observed in Müller cells.

Previously, it has been shown that the conditional knock-out of VEGF in Müller cells of mice reduced the expression of inflammatory markers like TNF α or ICAM1 compared to diabetic control mice, indicating a pro-inflammatory effect of VEGF on Müller cells (Bai et al., 2009; Wang et al., 2010). Here we could show that VEGF induced the Müller cell line MIO-M1 to secrete proteins associated with immune effector processes like IFN γ , B2M, HRNR, and complement-associated proteins like

SERPING1 and complement factor H (FH). Furthermore, ICAM1 was more abundant in our proteome data of MIO-M1 cells and pRMG treated with VEGF compared to the respective control cells. Thus, we were able to confirm the pro-inflammatory role of VEGF in Müller cells.

Overall, we observed that MIO-M1 cells secreted TNF α upon stimulation with VEGF, IL-6, and the TGF β isoforms 2 and 3. Increased levels of TNF α were previously identified in the vitreous of DR patients (Demircan et al., 2006). Furthermore, Müller cells have been reported to secrete increased amounts of VEGF and TNF α under stress conditions like inflammation or hyperglycemia, thereby promoting retinal inflammation (Zhang et al., 2006; Wang et al., 2010; Zhong et al., 2012; He et al., 2015; Kelly et al., 2018; Liu et al., 2021). Our results show that TNF α induced MIO-M1 cells to secrete inflammatory proteins but also proteins associated with tissue development like Leukemia Inhibitory Factor (LIF), Follistatin (FST), Neuregulin 1 (NRG1), or Pleiotrophin (PTN), to name but a few. Thus, our data suggest a pleiotropic role of TNF α in Müller cells.

TGF β s regulate early embryogenesis, maintenance and regeneration of mature tissues, and various disease processes (Gilbert et al., 2016). TGF β 1 has been described to be anti-inflammatory, inducing immune tolerance in the periphery and preventing autoimmunity. Thus, knock out of TGF β 1 in mice induced autoantibodies and multifocal inflammatory disease in many tissues, eventually causing the mice to die within 4 weeks of age (Yaswen et al., 1996). In our *in vitro* model, treatment of MIO-M1 cells with TGF β 1 induced secretion of CCL2 and therefore might result in the recruitment of leukocytes. Simultaneously, TGF β 1 enhanced the secretion of anti-inflammatory proteins like TNF Alpha Induced Protein 6 (TNFAIP6) or LIF in Müller cells. In contrast, TGF β 2 and TGF β 3 also promoted immune system processes in MIO-M1 cells by inducing secretion of pro-inflammatory cytokines TNF α , CXCL8, CXCL10 and IFN γ . It has been shown that TGF β 2 acts immunomodulatory in aqueous humor by decreasing the expression of IL-6, CXCL1, CCL2, G-CSF and IGFBP-5 (Yamagami et al., 2004). However, we demonstrated that treatment of Müller cells with TGF β 2 induced expression of IL-6 and CCL2, suggesting a complex and diverse role of TGF β 2 signaling in the eye. Although TGF β isoforms are closely related (sharing 71–79% sequence identity), have similar three-dimensional structures and signal canonically through the same receptor (Huang et al., 2014), our secretome analyses provide evidence that they affect Müller cells differentially. Latent TGF β binds Thrombospondin 1 (THBS1), augmenting its activation (Schultz-Cherry and Murphy-Ullrich, 1993; Schultz-Cherry et al., 1994; Murphy-Ullrich and Downs, 2015). Intriguingly, in our study, all three TGF β s elevate the abundance of THBS1 indicating a positive feedback loop. Recently, transcriptome analysis linked the expression of TGF β isoforms of mice to activation of different signaling cascades. While TGF β 1 and TGF β 2 evoked the non-canonical p38MAPK signaling pathway, which has been linked to gliosis, TGF β 3 induced the SMAD canonical signaling pathway for TGF β s in mice (Kaminska et al., 2009; Conedera et al., 2021). During glaucoma, the aqueous humor contains elevated levels of

TGF β 2, exceeding levels for homeostatic signaling (Tripathi et al., 1994; Murphy-Ullrich and Downs, 2015). Thereby, TGF β 2 has been associated with pathological remodeling of the trabecular meshwork and the optical nerve head (Murphy-Ullrich and Downs, 2015). Furthermore, it stimulated secretion of extracellular matrix proteins by astrocytes and cells of the lamina cribrosa (Fuchshofer et al., 2005; Fuchshofer, 2011; Zode et al., 2011; Fuchshofer and Tamm, 2012). Our data suggest that Müller cells also contribute to the remodeling of the extracellular matrix as stimulation with TGF β 1 and TGF β 3 resulted in enhanced secretion of extracellular matrix proteins like Fibrillin-2 (FBN2), various keratins, and collagens. Furthermore, they simultaneously enhanced the turnover of extracellular matrix by inducing the secretion of the Matrix Metalloprotease-1 (MMP1) and MMP2. Previously, MMP2 has been described to be elevated in DR patients and to promote the pathogenesis of DR by inducing mitochondrial dysfunction and apoptosis of retinal capillary cells (Mohammad and Kowluru, 2010). Intriguingly, our IPA also indicates that the canonical pathway for mitochondrial dysfunction is enriched in Müller cells upon stimulation with all TGF β isoforms. However, this is not solely due to the enhanced secretion of MMP2, since mitochondrial dysfunction is enriched in Müller cells by all tested cytokines, whereas TGF β s exclusively induce MMP2.

Although our data show no contribution of Müller cells to elevated IL-10 secretion upon stimulation with the tested cytokines, IL-10 induced proteins associated with tissue development, cell adhesion, and angiogenesis in MIO-M1 cells, namely Corneodesmosin (CDSN), LIF, PTN, and various collagens, to name a few. In line with this, it has been shown that IL-10 is involved in the pathological angiogenesis during the postnatal development by modulating the macrophage response to hypoxia (Dace et al., 2008). Thus, we hypothesize that IL-10 might also be involved in the abnormal angiogenesis during DR.

Previously, it has been shown that the canonically anti-inflammatory IL-4 can potentiate cytokine and chemokine production in macrophages following a pro-inflammatory stimulus (Major et al., 2002; Gadani et al., 2012; Luzina et al., 2012). In line with this, we observed increased abundances of many pro-inflammatory proteins like IFN γ , S100A9, S100A7, CXCL10, and Lysozyme C (LYZ) upon stimulation of MIO-M1 cells with IL-4, indicating that IL-4 does not exert an anti- but a pro-inflammatory influence in these cells. Thus, IL-4 might potentiate pro-inflammatory secretion in Müller cells similar to pro-inflammatory stimulated macrophages (Major et al., 2002; Gadani et al., 2012; Luzina et al., 2012). The similarities of Müller cells and macrophages upon IL-4 treatment should be investigated in more detail in future studies. Interestingly, MIO-M1 cells did not secrete the anti-inflammatory interleukin IL-4 upon treatment with the various tested cytokines. Secretion of pro-inflammatory IL-6 by Müller cells has been described upon treatment with IL-1 β or LPS (Yoshida et al., 2001). Furthermore, elevated levels of IL-6 were found in the vitreous and serum of DR patients and even further increased in patients suffering from proliferative DR (Yao et al., 2019). Here we show that IFN γ , TNF α , TGF β 2, and TGF β 3 also induced the secretion of IL-6 in MIO-M1 cells. Previously, it was shown that IL1 β induced IL-6

through activation of the p38MAPK signaling pathway (Liu et al., 2015). The murine TGF β isoforms 1 and 2 also activated the p38MAPK signaling in Müller cells of mice (Conedera et al., 2021). Thus, the involvement of p38MAPK signaling in secretion of IL-6 by Müller cells should be addressed in further studies. Brandon and colleagues demonstrated induction of VEGF by IL-6 in Müller cells, especially under hyperglycemic conditions, preventing Müller cells from glucose toxicity (Coughlin et al., 2019). In contrast, our analysis revealed no VEGF secretion by MIO-M1 cells upon IL-6 treatment. High glucose concentrations of 25 mM potentiated the induction of VEGF by IL-6 (Coughlin et al., 2019). However, by default the standard culture medium used in our study has a D-glucose concentration of 25 mM. Thus, an adaption of MIO-M1 cells to these conditions might have occurred negating the induction of VEGF by IL-6.

Elevated levels of IFN γ in the vitreous of DR patients have been described previously (Wu et al., 2017; Ucgun et al., 2020). In our study, we could observe distinctly elevated IFN γ secretion only after stimulation with IFN γ . Treatment with IFN γ furthermore induced the secretion of CXCL9, CXCL10, IL-6 and complement subcomponent C1r in MIO-M1 cells and pRMG.

Interestingly, we observed an induction of CX3CL1 in the whole-cell lysates and in the secretomes. Specifically, except for TGF β 1 and TGF β 2, all stimulants used in this study induced expression of CX3CL1 in the cell proteome of MIO-M1 cells, while only IFN γ and TNF α treatment resulted in significantly higher abundance of CX3CL1 in the secretome as well. CX3CL1 is a membrane-bound chemokine, which functions as an adhesion molecule for leukocytes, but can also be proteolytically cleaved, resulting in a soluble form with chemotactic function (Bazan et al., 1997; Imai et al., 1997). Circulating CD11b⁺ leukocytes that are involved in leukostasis in DR express higher levels of CX3CR1 in diabetic mice compared to controls (Serra et al., 2012). Thus, membrane-bound CX3CL1 on the surface of Müller cells might be involved in leukostasis in DR. In a previous study, incubation of microglia with Müller cell supernatant containing secreted CX3CL1 resulted in the upregulation of the respective receptor CX3CR1 in microglia. The authors proposed that Müller cells might be able to promote microglial motility via the chemotactic effect of CX3CL1 (Zhang et al., 2018). Thus, secretion of CX3CL1 from Müller cells might contribute to chronic retinal inflammation by recruiting peripheral inflammatory cells and microglia. Another route of communication between microglia/macrophages and Müller cells could be local changes in complement expression. We recently demonstrated, that Müller cells in the mouse retina are the main producers of complement components of the classical (C1s, C4), the alternative pathway (FB) and C3 as the central component to all pathways under homeostatic, but also under ischemic stress conditions (Pauly et al., 2019). In the retina, it is the microglia that by far express highest levels of complement receptors including ITGAM (alias CD11b), C3aR, C5aR1 and C5aR2 (Pauly et al., 2019). In our present study, TNF α and IFN γ triggered the most prominent effects on complement expression consistently in MIO-M1 and pRMG. Given that *in vivo* microglia and potentially other immune cell serve as major source of TNF α

and IFN γ (Kaczmarek-Hajek et al., 2018) (resource data from Cowan et al. (2020) at <https://data.iob.ch>), the strong effect of these cytokines on Müller cells could be central to coordinate the tissue immune homeostasis in pathologies. In this context, the enhanced expression of activating complement components by Müller cells could serve as feedback mechanisms towards microglia in turn modulating their activation profile. Taken together, our results point towards a pro-inflammatory phenotype of Müller cells, which is in line with a previous study, where we analyzed the surfaceome of primary equine Müller cells and MIO-M1 cells after stimulation with Lipopolysaccharide (Lorenz et al., 2021b). While the surfaceome of Müller cells in this previous study revealed expression of MHC class I and II as well as costimulatory molecules especially in primary equine Müller cells, we could now further complement these results with LC-MS/MS-analyses of whole cell lysates and of cell supernatants, confirming an antigen-presenting phenotype of Müller cells. While stimulation with LPS resulted in enhanced expression of MHC class II molecules in primary equine Müller cells, no MHC class II molecules could be identified in MIO-M1 cells upon LPS treatment (Lorenz et al., 2021b). In contrast, stimulation with IFN γ in this study induced the expression of proteins that are associated with both MHC class I and MHC class II antigen presentation in pRMG as well as in MIO-M1 cells. This is in accordance with an early study that demonstrated the induction of MHC class I and MHC class II molecules in primary human Müller cells by IFN γ *in vitro* (Mano et al., 1991). In contrast to MIO-M1 cells, pRMG also showed basal expression of MHC class II without stimulation. Thus, our data demonstrate that Müller cells exhibit several criteria for atypical antigen-presenting cells (Kambayashi and Laufer, 2014). Furthermore, our proteomic analysis revealed significantly higher abundance of the costimulatory molecule CD40 in pRMG after stimulation with IFN γ . In contrast to the porcine dataset, we could not identify CD40 in the MIO-M1 cells. As CD40 expression has already been shown in primary human Müller cells, our result might be due to the dedifferentiation of immortalized cells in culture (Portillo et al., 2014). Our data confirm that Müller cells are crucially involved in immunological processes in the retina as well, as they possess an antigen processing and presenting machinery and secrete pro-inflammatory cytokines (Karlstetter et al., 2015). We have previously shown that the cultivation of primary porcine Müller cells under hyperglycemic conditions resulted in higher expression levels of MHC class II molecules, pointing towards an immunologically activated state of Müller cells in DR (Sagmeister et al., 2021).

Pro-inflammatory stimulation of Müller cells resulted in the enrichment of proteins and pathways that are associated with the formation and maturation of phagosomes. Previously, Müller cells have been described to be phagocytic cells, capable of phagocytosing cell debris, dead photoreceptor cells and even bacteria (Singh et al., 2014; Bejarano-Escobar et al., 2017; Sakami et al., 2019). Our IPA showed that proteins of phagocytosis pathways in Müller cells are induced upon stimulation with various cytokines. Furthermore, phagocytosis is not only clathrin- but also caveolar-mediated. Since our data showed enrichment of phagocytic pathways, as well as the

canonical antigen presentation pathway, it is possible that Müller cells present exogenous peptides on MHC class II to CD4⁺ T helper cells. Intriguingly, phagocytosis of dead photoreceptors would also allow Müller cells to present proteins expressed by photoreceptors on MHC class II, and via cross-presentation on MHC class I (Larsson et al., 2001; Gutiérrez-Martínez et al., 2015). Further studies should address, whether Müller cells are sufficient to stimulate alloreactive naïve T cells or memory T cells (Kambayashi and Laufer, 2014).

Oxidative stress and reactive oxygen species (ROS) are known to play a central role during the pathogenesis of DR (Cecilia et al., 2019). Rat-derived Müller cells under hyperglycemic conditions developed mitochondrial dysfunction and oxidative stress, causing swelling and eventually apoptosis of the cells (Krügel et al., 2011; Tien et al., 2017). Mitochondrial dysfunction can lead to ROS production, which then promotes inflammatory response by activation of NF- κ B and release of pro-inflammatory cytokines (Behl and Kotwani, 2015; Homme et al., 2018). Our analysis revealed that proteins associated with mitochondrial dysfunction were enriched after treatment of pRMG with all tested cytokines. Furthermore, two significantly enriched pathways in our data sets are associated with reactive oxygen species, namely “NRF2 mediated Oxidative Stress Response” and “Production of Nitric Oxide and Reactive Oxygen Species in Macrophages”. Intriguingly, Müller cells have previously been found to regulate the ROS levels via Nrf2 and to be more resistant to ROS formation compared to photoreceptor cells or bipolar cells (Wang et al., 2015; Grosche et al., 2016). In line with this, we showed that treatment with IL-4, TGF β 2, TGF β 3, TNF α and VEGF inhibited death receptor signaling in pRMG. Phagocytic cells often produce ROS to protect themselves from pathogens (Geng et al., 2015). Furthermore, macrophages stabilize cytosolic Nrf2 to be more resistant against ROS (Wang et al., 2019). Since Müller cells have been shown to be phagocytic, we propose that induction of ROS in these cells also serves as a defense mechanism (Singh et al., 2014; Bejarano-Escobar et al., 2017; Sakami et al., 2019).

Our hypothesis generating approach indicates the release of many pro-inflammatory cytokines *in vitro* by Müller cells, as well as Müller cells with the potential to present peptides on MHC class I and II to T cells. This might have implications for the pathogenesis of DR or, in a broader context, on chronic retinal inflammation in general. However, further studies using diseased retinas are necessary in order to show the influence of pro-inflammatory Müller cells on retinal inflammations.

In this study, we used both primary porcine Müller cells and the spontaneously immortalized human Müller cell line MIO-M1 that was established and described in the Moorfields Institute of Ophthalmology 2002 (Limb et al., 2002). Although MIO-M1 cells largely retain the phenotypic and functional characteristics of Müller cells *in vitro*, previous studies documented some characteristics of neuronal stem cells and expression of postmitotic neuronal cell markers in MIO-M1 cells (Limb et al., 2002; Lawrence et al., 2007; Hollborn et al., 2011). Furthermore, it has been shown that Müller cells tend to adapt to cell culture

conditions by reduced secretion of neurotrophic factors (Hauck et al., 2008; Merl et al., 2012). Our analysis revealed many proteins commonly regulated in pRMG and MIO-M1 cells, as well as pathways similarly enriched and regulated in both cells. However, we also observed effects specific for either MIO-M1 cells or pRMG. Thus, for example our IPA revealed that MIO-M1 cells decrease the activity of the significantly enriched canonical pathway oxidative phosphorylation, while it is amongst the most induced pathways of pRMG following treatment with the majority of tested cytokines. While these differences might originate from different adaption of MIO-M1 cells and pRMG to the cell culture conditions or the immortalization of MIO-M1 cells, it might as well be possible that they originate from differences in human and porcine Müller cells. Further studies should elaborate similarities and differences between freshly prepared primary human and porcine Müller cells.

Taken together, our in-depth proteomic profiling of MIO-M1 cells and pRMG revealed the capacity of Müller cells to react in a differentiated manner upon treatment with various growth factors and cytokines. Furthermore, we demonstrated a primarily pro-inflammatory phenotype of Müller cells, as they secreted a variety of pro-inflammatory cytokines, complement components and upregulated proteins associated with antigen processing and presentation, suggesting a function as atypical antigen-presenting cell in the course of retinal inflammation. Furthermore, we observed enrichment of proteins connected to mitochondrial dysfunction, as well as proteins related to the formation and maturation of phagosomes. Thus, Müller cells are capable of modulating immune responses in the retina, and may significantly contribute to chronic inflammation during DR.

DATA AVAILABILITY STATEMENT

The datasets presented in this study can be found in an online repository. The repository and accession number can be found below: <https://www.ebi.ac.uk/pride;PXD028390>.

AUTHOR CONTRIBUTIONS

Conceptualization, SH and CD; Formal analysis, SH; Funding acquisition, SH and CD; Investigation, AS, LL, CD, and SH; Project administration, SH; Supervision, SH; Visualization, AS; Writing—original draft, AS, LL, AG, and DP; Writing—review and editing, CD and SH. All authors have read and agreed to the published version of the manuscript.

FUNDING

This work was funded by Deutsche Forschungsgemeinschaft in the SPP 2127, grant numbers DFG DE 719/7-1 to CD, HA 6014/5-1 to SH, GR 4403/5-1 to AG and PA 1844/3-1 to DP.

ACKNOWLEDGMENTS

The authors would like to thank Adrian Sandbiller for providing porcine eye samples as well as Juliane Merl-Pham for critical discussions.

REFERENCES

- Bai, Y., Ma, J. X., Guo, J., Wang, J., Zhu, M., Chen, Y., et al. (2009). Müller Cell-Derived VEGF Is a Significant Contributor to Retinal Neovascularization. *J. Pathol.* 219 (4), 446–454. doi:10.1002/path.2611
- Bazan, J. F., Bacon, K. B., Hardiman, G., Wang, W., Soo, K., Rossi, D., et al. (1997). A New Class of Membrane-Bound Chemokine with a CX3C Motif. *Nature* 385 (6617), 640–644. doi:10.1038/385640a0
- Behl, T., and Kotwani, A. (2015). Exploring the Various Aspects of the Pathological Role of Vascular Endothelial Growth Factor (VEGF) in Diabetic Retinopathy. *Pharmacol. Res.* 99, 137–148. doi:10.1016/j.phrs.2015.05.013
- Bejarano-Escobar, R., Sánchez-Calderón, H., Otero-Arenas, J., Martín-Partido, G., and Francisco-Morcillo, J. (2017). Müller Glia and Phagocytosis of Cell Debris in Retinal Tissue. *J. Anat.* 231 (4), 471–483. doi:10.1111/joa.12653
- Benjamini, Y., Drai, D., Elmer, G., Kafkafi, N., and Golani, I. (2001). Controlling the False Discovery Rate in Behavior Genetics Research. *Behav. Brain Res.* 125 (1–2), 279–284. doi:10.1016/s0166-4328(01)00297-2
- Bringmann, A., Iandiev, I., Pannicke, T., Wurm, A., Hollborn, M., Wiedemann, P., et al. (2009). Cellular Signaling and Factors Involved in Müller Cell Gliosis: Neuroprotective and Detrimental Effects. *Prog. Retin. Eye Res.* 28 (6), 423–451. doi:10.1016/j.preteyeres.2009.07.001
- Bringmann, A., Pannicke, T., Grosche, J., Francke, M., Wiedemann, P., Skatchkov, S. N., et al. (2006). Müller Cells in the Healthy and Diseased Retina. *Prog. Retin. Eye Res.* 25 (4), 397–424. doi:10.1016/j.preteyeres.2006.05.003
- Broadgate, S., Yu, J., Downes, S. M., and Halford, S. (2017). Unravelling the Genetics of Inherited Retinal Dystrophies: Past, Present and Future. *Prog. Retin. Eye Res.* 59, 53–96. doi:10.1016/j.preteyeres.2017.03.003
- Cecilia, O. M., José Alberto, C. G., José, N. P., Ernesto Germán, C. M., Ana Karen, L. C., Luis Miguel, R. P., et al. (2019). Oxidative Stress as the Main Target in Diabetic Retinopathy Pathophysiology. *J. Diabetes Res.* 2019, 8562408. doi:10.1155/2019/8562408
- Chen, M., Obasanmi, G., Armstrong, D., Lavery, N. J., Kissenpfennig, A., Lois, N., et al. (2019). STAT3 Activation in Circulating Myeloid-Derived Cells Contributes to Retinal Microvascular Dysfunction in Diabetes. *J. Neuroinflammation* 16 (1), 138. doi:10.1186/s12974-019-1533-1
- Conedera, F. M., Quintela Pousa, A. M., Presby, D. M., Mercader, N., Enzmann, V., and Tschopp, M. (2021). Diverse Signaling by TGF β Isoforms in Response to Focal Injury Is Associated with Either Retinal Regeneration or Reactive Gliosis. *Cell Mol Neurobiol* 41 (1), 43–62. doi:10.1007/s10571-020-00830-5
- Coughlin, B. A., Feenstra, D. J., and Mohr, S. (2017). Müller Cells and Diabetic Retinopathy. *Vis. Res.* 139, 93–100. doi:10.1016/j.visres.2017.03.013
- Coughlin, B. A., Trombley, B. T., and Mohr, S. (2019). Interleukin-6 (IL-6) Mediates protection against Glucose Toxicity in Human Müller Cells via Activation of VEGF-A Signaling. *Biochem. Biophys. Res. Commun.* 517 (2), 227–232. doi:10.1016/j.bbrc.2019.07.044
- Cowan, C. S., Renner, M., De Gennaro, M., Gross-Scherf, B., Goldblum, D., Hou, Y., et al. (2020). Cell Types of the Human Retina and its Organoids at Single-Cell Resolution. *Cell* 182 (6), 1623–e34. doi:10.1016/j.cell.2020.08.013
- Dace, D. S., Khan, A. A., Kelly, J., and Apte, R. S. (2008). Interleukin-10 Promotes Pathological Angiogenesis by Regulating Macrophage Response to Hypoxia during Development. *PLoS One* 3 (10), e3381. doi:10.1371/journal.pone.0003381
- Demircan, N., Safran, B. G., Soyulu, M., Ozcan, A. A., and Sizmaz, S. (2006). Determination of Vitreous Interleukin-1 (IL-1) and Tumour Necrosis Factor (TNF) Levels in Proliferative Diabetic Retinopathy. *Eye (Lond)* 20 (12), 1366–1369. doi:10.1038/sj.eye.6702138
- Di Pierdomenico, J., Martínez-Vacas, A., Hernández-Muñoz, D., Gómez-Ramírez, A. M., Valiente-Soriano, F. J., Agudo-Barriso, M., et al. (2020). Coordinated

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: <https://www.frontiersin.org/articles/10.3389/fphar.2021.771571/full#supplementary-material>

- Intervention of Microglial and Müller Cells in Light-Induced Retinal Degeneration. *Invest. Ophthalmol. Vis. Sci.* 61 (3), 47. doi:10.1167/iovs.61.3.47
- Duncan, J. L., Pierce, E. A., Laster, A. M., Daiger, S. P., Birch, D. G., Ash, J. D., et al. (2018). Inherited Retinal Degenerations: Current Landscape and Knowledge Gaps. *Transl. Vis. Sci. Technol.* 7 (4), 6. doi:10.1167/tvst.7.4.6
- Eastlake, K., Banerjee, P. J., Angbohang, A., Charteris, D. G., Khaw, P. T., and Limb, G. A. (2016). Müller Glia as an Important Source of Cytokines and Inflammatory Factors Present in the Gliotic Retina during Proliferative Vitreoretinopathy. *Glia* 64 (4), 495–506. doi:10.1002/glia.22942
- Eberhardt, C., Amann, B., Stangassinger, M., Hauck, S. M., and Deeg, C. A. (2012). Isolation, Characterization and Establishment of an Equine Retinal Glial Cell Line: a Prerequisite to Investigate the Physiological Function of Müller Cells in the Retina. *J. Anim. Physiol. Anim. Nutr. (Berl)* 96 (2), 260–269. doi:10.1111/j.1439-0396.2011.01147.x
- Eisen, M. B., Spellman, P. T., Brown, P. O., and Botstein, D. (1998). Cluster Analysis and Display of Genome-wide Expression Patterns. *Proc. Natl. Acad. Sci. U S A.* 95 (25), 14863–14868. doi:10.1073/pnas.95.25.14863
- Fisher, R. A. (1922). On the Interpretation of χ^2 from Contingency Tables, and the Calculation of P. *J. R. Stat. Soc.* 85 (1), 87–94. doi:10.2307/2340521
- Forrester, J. V., Kuffova, L., and Delibegovic, M. (2020). The Role of Inflammation in Diabetic Retinopathy. *Front. Immunol.* 11, 583687. doi:10.3389/fimmu.2020.583687
- Fuchshofer, R., Birke, M., Welge-Lüssen, U., Kook, D., and Lütjen-Drecoll, E. (2005). Transforming Growth Factor-Beta 2 Modulated Extracellular Matrix Component Expression in Cultured Human Optic Nerve Head Astrocytes. *Invest. Ophthalmol. Vis. Sci.* 46 (2), 568–578. doi:10.1167/iovs.04-0649
- Fuchshofer, R., and Tamm, E. R. (2012). The Role of TGF- β in the Pathogenesis of Primary Open-Angle Glaucoma. *Cell Tissue Res* 347 (1), 279–290. doi:10.1007/s00441-011-1274-7
- Fuchshofer, R. (2011). The Pathogenic Role of Transforming Growth Factor-B2 in Glaucomatous Damage to the Optic Nerve Head. *Exp. Eye Res.* 93 (2), 165–169. doi:10.1016/j.exer.2010.07.014
- Gadani, S. P., Cronk, J. C., Norris, G. T., and Kipnis, J. (2012). IL-4 in the Brain: a Cytokine to Remember. *J. Immunol.* 189 (9), 4213–4219. doi:10.4049/jimmunol.1202246
- GBaVI, Collaborators. (2021). Causes of Blindness and Vision Impairment in 2020 and Trends over 30 years, and Prevalence of Avoidable Blindness in Relation to VISION 2020: the Right to Sight: an Analysis for the Global Burden of Disease Study. *Lancet Glob. Health* 9 (2), e144–e60.
- Geng, J., Sun, X., Wang, P., Zhang, S., Wang, X., Wu, H., et al. (2015). Kinases Mst1 and Mst2 Positively Regulate Phagocytic Induction of Reactive Oxygen Species and Bactericidal Activity. *Nat. Immunol.* 16 (11), 1142–1152. doi:10.1038/ni.3268
- Gerhardinger, C., Costa, M. B., Coulombe, M. C., Toth, I., Hoehn, T., and Grosu, P. (2005). Expression of Acute-phase Response Proteins in Retinal Müller Cells in Diabetes. *Invest. Ophthalmol. Vis. Sci.* 46 (1), 349–357. doi:10.1167/iovs.04-0860
- Ghaseminejad, F., Kaplan, L., Pfaller, A. M., Hauck, S. M., and Grosche, A. (2020). The Role of Müller Cell Glucocorticoid Signaling in Diabetic Retinopathy. *Graefes Arch. Clin. Exp. Ophthalmol.* 258 (2), 221–230. doi:10.1007/s00417-019-04521-w
- Gilbert, R. W. D., Vickaryous, M. K., and Vilorio-Petit, A. M. (2016). Signaling by Transforming Growth Factor Beta Isoforms in Wound Healing and Tissue Regeneration. *J. Dev. Biol.* 4 (2). doi:10.3390/jdb4020021
- Grosche, A., Hauser, A., Lepper, M. F., Mayo, R., von Toerne, C., Merl-Pham, J., et al. (2016). The Proteome of Native Adult Müller Glial Cells from Murine Retina. *Mol. Cell Proteomics* 15 (2), 462–480. doi:10.1074/mcp.M115.052183
- Gutiérrez-Martínez, E., Planès, R., Anselmi, G., Reynolds, M., Menezes, S., Adiko, A. C., et al. (2015). Cross-Presentation of Cell-Associated Antigens by MHC

- Class I in Dendritic Cell Subsets. *Front. Immunol.* 6, 363. doi:10.3389/fimmu.2015.00363
- Hauck, S. M., Gloeckner, C. J., Harley, M. E., Schoeffmann, S., Boldt, K., Ekstrom, P. A., et al. (2008). Identification of Paracrine Neuroprotective Candidate Proteins by a Functional Assay-Driven Proteomics Approach. *Mol. Cell Proteomics* 7 (7), 1349–1361. doi:10.1074/mcp.M700456-MCP200
- Hauck, S. M., Schoeffmann, S., Amann, B., Stangassinger, M., Gerhards, H., Ueffing, M., et al. (2007). Retinal Müller Glial Cells Trigger the Hallmark Inflammatory Process in Autoimmune Uveitis. *J. Proteome Res.* 6 (6), 2121–2131. doi:10.1021/pr060668y
- Hauck, S. M., Suppmann, S., and Ueffing, M. (2003). Proteomic Profiling of Primary Retinal Müller Glia Cells Reveals a Shift in Expression Patterns upon Adaptation to *In Vitro* Conditions. *Glia* 44 (3), 251–263. doi:10.1002/glia.10292
- He, J., Wang, H., Liu, Y., Li, W., Kim, D., and Huang, H. (2015). Blockade of Vascular Endothelial Growth Factor Receptor 1 Prevents Inflammation and Vascular Leakage in Diabetic Retinopathy. *J. Ophthalmol.* 2015, 605946. doi:10.1155/2015/605946
- Hewitt, E. W. (2003). The MHC Class I Antigen Presentation Pathway: Strategies for Viral Immune Evasion. *Immunology* 110 (2), 163–169. doi:10.1046/j.1365-2567.2003.01738.x
- Hollborn, M., Ulbricht, E., Rillich, K., Dukic-Stefanovic, S., Wurm, A., Wagner, L., et al. (2011). The Human Müller Cell Line MIO-M1 Expresses Opsins. *Mol. Vis.* 17, 2738–2750.
- Homme, R. P., Singh, M., Majumder, A., George, A. K., Nair, K., Sandhu, H. S., et al. (2018). Remodeling of Retinal Architecture in Diabetic Retinopathy: Disruption of Ocular Physiology and Visual Functions by Inflammatory Gene Products and Pyroptosis. *Front. Physiol.* 9, 1268. doi:10.3389/fphys.2018.01268
- Huang, T., Schor, S. L., and Hinck, A. P. (2014). Biological Activity Differences between TGF-B1 and TGF-B3 Correlate with Differences in the Rigidity and Arrangement of Their Component Monomers. *Biochemistry* 53 (36), 5737–5749. doi:10.1021/bi500647d
- Imai, T., Hieshima, K., Haskell, C., Baba, M., Nagira, M., Nishimura, M., et al. (1997). Identification and Molecular Characterization of Fractalkine Receptor CX3CR1, Which Mediates Both Leukocyte Migration and Adhesion. *Cell* 91 (4), 521–530. doi:10.1016/s0092-8674(00)80438-9
- Kaczmarek-Hajek, K., Zhang, J., Kopp, R., Grosche, A., Rissiek, B., Saul, A., et al. (2018). Re-evaluation of Neuronal P2X7 Expression Using Novel Mouse Models and a P2X7-specific Nanobody. *Elife* 7. doi:10.7554/eLife.36217
- Käll, L., Canterbury, J. D., Weston, J., Noble, W. S., and MacCoss, M. J. (2007). Semi-supervised Learning for Peptide Identification from Shotgun Proteomics Datasets. *Nat. Methods* 4 (11), 923–925. doi:10.1038/nmeth1113
- Kambayashi, T., and Laufer, T. M. (2014). Atypical MHC Class II-Expressing Antigen-Presenting Cells: Can Anything Replace a Dendritic Cell. *Nat. Rev. Immunol.* 14 (11), 719–730. doi:10.1038/nri3754
- Kaminska, B., Gozdz, A., Zawadzka, M., Ellert-Miklaszewska, A., and Lipko, M. (2009). MAPK Signal Transduction Underlying Brain Inflammation and Gliosis as Therapeutic Target. *Anat. Rec. (Hoboken)* 292 (12), 1902–1913. doi:10.1002/ar.21047
- Karlstetter, M., Scholz, R., Rutar, M., Wong, W. T., Provis, J. M., and Langmann, T. (2015). Retinal Microglia: Just Bystander or Target for Therapy. *Prog. Retin. Eye Res.* 45, 30–57. doi:10.1016/j.preteyeres.2014.11.004
- Kelly, K., Wang, J. J., and Zhang, S. X. (2018). The Unfolded Protein Response Signaling and Retinal Müller Cell Metabolism. *Neural Regen. Res.* 13 (11), 1861–1870. doi:10.4103/1673-5374.239431
- Kinuthia, U. M., Wolf, A., and Langmann, T. (2020). Microglia and Inflammatory Responses in Diabetic Retinopathy. *Front. Immunol.* 11, 564077. doi:10.3389/fimmu.2020.564077
- Kleinwort, K. J. H., Amann, B., Hauck, S. M., Hirmer, S., Blutke, A., Renner, S., et al. (2017). Retinopathy with central Oedema in an INS C94Y Transgenic Pig Model of Long-Term Diabetes. *Diabetologia* 60 (8), 1541–1549. doi:10.1007/s00125-017-4290-7
- Konigsberg, I. R., Borie, R., Walts, A. D., Cardwell, J., Rojas, M., Metzger, F., et al. (2021). Molecular Signatures of Idiopathic Pulmonary Fibrosis. *Am. J. Respir. Cell Mol. Biol.* doi:10.1165/rcmb.2020-0546oc
- Krämer, A., Green, J., Pollard, J., Jr., and Tugendreich, S. (2014). Causal Analysis Approaches in Ingenuity Pathway Analysis. *Bioinformatics* 30 (4), 523–530. doi:10.1093/bioinformatics/btt703
- Krügel, K., Wurm, A., Pannicke, T., Hollborn, M., Karl, A., Wiedemann, P., et al. (2011). Involvement of Oxidative Stress and Mitochondrial Dysfunction in the Osmotic Swelling of Retinal Glial Cells from Diabetic Rats. *Exp. Eye Res.* 92 (1), 87–93. doi:10.1016/j.exer.2010.11.007
- Larsson, M., Fonteneau, J. F., and Bhardwaj, N. (2001). Dendritic Cells Resurrect Antigens from Dead Cells. *Trends Immunol.* 22 (3), 141–148. doi:10.1016/s1471-4906(01)01860-9
- Lawrence, J. M., Singhal, S., Bhatia, B., Keegan, D. J., Reh, T. A., Luthert, P. J., et al. (2007). MIO-M1 Cells and Similar Müller Glial Cell Lines Derived from Adult Human Retina Exhibit Neural Stem Cell Characteristics. *Stem Cells* 25 (8), 2033–2043. doi:10.1634/stemcells.2006-0724
- Lechner, J., O'Leary, O. E., and Stitt, A. W. (2017). The Pathology Associated with Diabetic Retinopathy. *Vis. Res.* 139, 7–14. doi:10.1016/j.visres.2017.04.003
- Limb, G. A., Salt, T. E., Munro, P. M., Moss, S. E., and Khaw, P. T. (2002). *In Vitro* Characterization of a Spontaneously Immortalized Human Müller Cell Line (MIO-M1). *Invest. Ophthalmol. Vis. Sci.* 43 (3), 864–869.
- Liu, X., Ye, F., Xiong, H., Hu, D. N., Limb, G. A., Xie, T., et al. (2015). IL-1 β Induces IL-6 Production in Retinal Müller Cells Predominantly through the Activation of P38 MAPK/NF- κ B Signaling Pathway. *Exp. Cell Res.* 331 (1), 223–231. doi:10.1016/j.yexcr.2014.08.040
- Liu, Y., Li, L., Pan, N., Gu, J., Qiu, Z., Cao, G., et al. (2021). TNF- α Released from Retinal Müller Cells Aggravates Retinal Pigment Epithelium Cell Apoptosis by Upregulating Mitophagy during Diabetic Retinopathy. *Biochem. Biophys. Res. Commun.* 561, 143–150. doi:10.1016/j.bbrc.2021.05.027
- Lorenz, L., Amann, B., Hirmer, S., Degroote, R. L., Hauck, S. M., and Deeg, C. A. (2021). NEU1 Is More Abundant in Uveitic Retina with Concomitant Desialylation of Retinal Cells. *Glycobiology*. doi:10.1093/glycob/cwab014
- Lorenz, L., Hirmer, S., Schmalen, A., Hauck, S. M., and Deeg, C. A. (2021). Cell Surface Profiling of Retinal Müller Glial Cells Reveals Association to Immune Pathways after LPS Stimulation. *Cells* 10 (3). doi:10.3390/cells10030711
- Lunney, J. K., Ho, C. S., Wysocki, M., and Smith, D. M. (2009). Molecular Genetics of the Swine Major Histocompatibility Complex, the SLA Complex. *Dev. Comp. Immunol.* 33 (3), 362–374. doi:10.1016/j.dci.2008.07.002
- Luzina, I. G., Keegan, A. D., Heller, N. M., Rook, G. A., Shea-Donohue, T., and Atamas, S. P. (2012). Regulation of Inflammation by Interleukin-4: a Review of "alternatives". *J. Leukoc. Biol.* 92 (4), 753–764. doi:10.1189/jlb.0412214
- Major, J., Fletcher, J. E., and Hamilton, T. A. (2002). IL-4 Pretreatment Selectively Enhances Cytokine and Chemokine Production in Lipopolysaccharide-Stimulated Mouse Peritoneal Macrophages. *J. Immunol.* 168 (5), 2456–2463. doi:10.4049/jimmunol.168.5.2456
- Mano, T., Tokuda, N., and Puro, D. G. (1991). Interferon-gamma Induces the Expression of Major Histocompatibility Antigens by Human Retinal Glial Cells. *Exp. Eye Res.* 53 (5), 603–607. doi:10.1016/0014-4835(91)90219-5
- Merl, J., Ueffing, M., Hauck, S. M., and von Toerne, C. (2012). Direct Comparison of MS-based Label-free and SILAC Quantitative Proteome Profiling Strategies in Primary Retinal Müller Cells. *Proteomics* 12 (12), 1902–1911. doi:10.1002/pmic.201100549
- Middleton S. Porcine ophthalmology (2010). *Veterinary Clinics of North America: Food Animal Practice. Porcine Ophthalmol.* 26 (3), 557–572. doi:10.1016/j.cvfa.2010.09.002
- Mizutani, M., Gerhardinger, C., and Lorenzi, M. (1998). Müller Cell Changes in Human Diabetic Retinopathy. *Diabetes* 47 (3), 445–449. doi:10.2337/diabetes.47.3.445
- Mohammad, G., and Kowluru, R. A. (2010). Matrix Metalloproteinase-2 in the Development of Diabetic Retinopathy and Mitochondrial Dysfunction. *Lab. Invest.* 90 (9), 1365–1372. doi:10.1038/labinvest.2010.89
- Murphy-Ullrich, J. E., and Downs, J. C. (2015). The Thrombospondin1-TGF- β Pathway and Glaucoma. *J. Ocul. Pharmacol. Ther.* 31 (7), 371–375. doi:10.1089/jop.2015.0016
- Natoli, R., Fernando, N., Madigan, M., Chu-Tan, J. A., Valter, K., Provis, J., et al. (2017). Microglia-derived IL-1 β Promotes Chemokine Expression by Müller Cells and RPE in Focal Retinal Degeneration. *Mol. Neurodegener.* 12 (1), 31. doi:10.1186/s13024-017-0175-y

- Navarro, P., Trevisan-Herraz, M., Bonzon-Kulichenko, E., Núñez, E., Martínez-Acedo, P., Pérez-Hernández, D., et al. (2014). General Statistical Framework for Quantitative Proteomics by Stable Isotope Labeling. *J. Proteome Res.* 13 (3), 1234–1247. doi:10.1021/pr4006958
- Newman, E., and Reichenbach, A. (1996). The Müller Cell: a Functional Element of the Retina. *Trends Neurosci.* 19 (8), 307–312. doi:10.1016/0166-2236(96)10040-0
- Olivares-González, L., Velasco, S., Campillo, I., and Rodrigo, R. (2021). Retinal Inflammation, Cell Death and Inherited Retinal Dystrophies. *Int. J. Mol. Sci.* 22 (4). doi:10.3390/ijms22042096
- Pauly, D., Agarwal, D., Dana, N., Schäfer, N., Biber, J., Wunderlich, K. A., et al. (2019). Cell-Type-Specific Complement Expression in the Healthy and Diseased Retina. *Cell Rep* 29 (9), 2835–e4. doi:10.1016/j.celrep.2019.10.084
- Portillo, J. A., Greene, J. A., Okenka, G., Miao, Y., Sheibani, N., Kern, T. S., et al. (2014). CD40 Promotes the Development of Early Diabetic Retinopathy in Mice. *Diabetologia* 57 (10), 2222–2231. doi:10.1007/s00125-014-3321-x
- Reichenbach, A., and Bringmann, A. (2020). Glia of the Human Retina. *Glia* 68 (4), 768–796. doi:10.1002/glia.23727
- Renner, S., Blutke, A., Clauss, S., Deeg, C. A., Kemter, E., Merkus, D., et al. (2020). Porcine Models for Studying Complications and Organ Crosstalk in Diabetes Mellitus. *Cel Tissue Res.* doi:10.1007/s00441-019-03158-9
- Roberge, F. G., Caspi, R. R., and Nussenblatt, R. B. (1988). Glial Retinal Müller Cells Produce IL-1 Activity and Have a Dual Effect on Autoimmune T Helper Lymphocytes. Antigen Presentation Manifested after Removal of Suppressive Activity. *J. Immunol.* 140 (7), 2193–2196.
- Roche, P. A., and Furuta, K. (2015). The Ins and Outs of MHC Class II-Mediated Antigen Processing and Presentation. *Nat. Rev. Immunol.* 15 (4), 203–216. doi:10.1038/nri3818
- Rutar, M., Natoli, R., Chia, R. X., Valter, K., and Provis, J. M. (2015). Chemokine-mediated Inflammation in the Degrading Retina Is Coordinated by Müller Cells, Activated Microglia, and Retinal Pigment Epithelium. *J. Neuroinflammation* 12 (1), 8. doi:10.1186/s12974-014-0224-1
- Ruzafa, N., Pereiro, X., Lepper, M. F., Hauck, S. M., and Vecino, E. (2018). A Proteomics Approach to Identify Candidate Proteins Secreted by Müller Glia that Protect Ganglion Cells in the Retina. *PROTEOMICS* 18 (11), e1700321. doi:10.1002/pmic.201700321
- Sagmeister, S., Merl-Pham, J., Petrera, A., Deeg, C. A., and Hauck, S. M. (2021). High Glucose Treatment Promotes Extracellular Matrix Proteome Remodeling in Müller Glial Cells. *PeerJ* 9, e11316. doi:10.7717/peerj.11316
- Sakami, S., Imanishi, Y., and Palczewski, K. (2019). Müller Glia Phagocytose Dead Photoreceptor Cells in a Mouse Model of Retinal Degenerative Disease. *FASEB J.* 33 (3), 3680–3692. doi:10.1096/fj.201801662R
- Saldanha, A. J. (2004). Java Treeview—Extensible Visualization of Microarray Data. *Bioinformatics* 20 (17), 3246–3248. doi:10.1093/bioinformatics/bth349
- Schultz-Cherry, S., Lawler, J., and Murphy-Ullrich, J. E. (1994). The Type 1 Repeats of Thrombospondin 1 Activate Latent Transforming Growth Factor-Beta. *J. Biol. Chem.* 269 (43), 26783–26788. doi:10.1016/s0021-9258(18)47087-1
- Schultz-Cherry, S., and Murphy-Ullrich, J. E. (1993). Thrombospondin Causes Activation of Latent Transforming Growth Factor-Beta Secreted by Endothelial Cells by a Novel Mechanism. *J. Cell Biol* 122 (4), 923–932. doi:10.1083/jcb.122.4.923
- Serra, A. M., Waddell, J., Manivannan, A., Xu, H., Cotter, M., and Forrester, J. V. (2012). CD11b+ Bone Marrow-Derived Monocytes Are the Major Leukocyte Subset Responsible for Retinal Capillary Leukostasis in Experimental Diabetes in Mouse and Express High Levels of CCR5 in the Circulation. *Am. J. Pathol.* 181 (2), 719–727. doi:10.1016/j.ajpath.2012.04.009
- Sigal, L. J. (2016). Activation of CD8 T Lymphocytes during Viral Infections. *Encyclopedia of Immunobiology*, 286–290. doi:10.1016/b978-0-12-374279-7.14009-3
- Singh, P. K., Shiha, M. J., and Kumar, A. (2014). Antibacterial Responses of Retinal Müller Glia: Production of Antimicrobial Peptides, Oxidative Burst and Phagocytosis. *J. Neuroinflammation* 11, 33. doi:10.1186/1742-2094-11-33
- Subirada, P. V., Paz, M. C., Ridano, M. E., Lorenc, V. E., Vaglianti, M. V., Barcelona, P. F., et al. (2018). A Journey into the Retina: Müller Glia Commanding Survival and Death. *Eur. J. Neurosci.* 47 (12), 1429–1443. doi:10.1111/ejn.13965
- Tien, T., Zhang, J., Muto, T., Kim, D., Sarthy, V. P., and Roy, S. (2017). High Glucose Induces Mitochondrial Dysfunction in Retinal Müller Cells: Implications for Diabetic Retinopathy. *Invest. Ophthalmol. Vis. Sci.* 58 (7), 2915–2921. doi:10.1167/iovs.16-21355
- Tripathi, R. C., Li, J., Chan, W. F., and Tripathi, B. J. (1994). Aqueous Humor in Glaucomatous Eyes Contains an Increased Level of TGF-Beta 2. *Exp. Eye Res.* 59 (6), 723–727. doi:10.1006/exer.1994.1158
- Ucgun, N. I., Zeki-Fikret, C., and Yildirim, Z. (2020). Inflammation and Diabetic Retinopathy. *Mol. Vis.* 26, 718–721.
- von Toerne, C., Menzler, J., Ly, A., Senninger, N., Ueffing, M., and Hauck, S. M. (2014). Identification of a Novel Neurotrophic Factor from Primary Retinal Müller Cells Using Stable Isotope Labeling by Amino Acids in Cell Culture (SILAC). *Mol. Cell Proteomics* 13 (9), 2371–2381. doi:10.1074/mcp.M113.033613
- Wang, J., Shanmugam, A., Markand, S., Zorrilla, E., Ganapathy, V., and Smith, S. B. (2015). Sigma 1 Receptor Regulates the Oxidative Stress Response in Primary Retinal Müller Glial Cells via NRF2 Signaling and System Xc(-), the Na(+)-independent Glutamate-Cystine Exchanger. *Free Radic. Biol. Med.* 86, 25–36. doi:10.1016/j.freeradbiomed.2015.04.009
- Wang, J., Xu, X., Elliott, M. H., Zhu, M., and Le, Y. Z. (2010). Müller Cell-Derived VEGF Is Essential for Diabetes-Induced Retinal Inflammation and Vascular Leakage. *Diabetes* 59 (9), 2297–2305. doi:10.2337/db09-1420
- Wang, M., Ma, W., Zhao, L., Fariss, R. N., and Wong, W. T. (2011). Adaptive Müller Cell Responses to Microglial Activation Mediate Neuroprotection and Coordinate Inflammation in the Retina. *J. Neuroinflammation* 8, 173. doi:10.1186/1742-2094-8-173
- Wang, P., Geng, J., Gao, J., Zhao, H., Li, J., Shi, Y., et al. (2019). Macrophage Achieves Self-protection against Oxidative Stress-Induced Ageing through the Mst-Nrf2 axis. *Nat. Commun.* 10 (1), 755. doi:10.1038/s41467-019-08680-6
- Weigand, M., Hauck, S. M., Deeg, C. A., and Degroote, R. L. (2021). Deviant Proteome Profile of Equine Granulocytes Associates to Latent Activation Status in Organ Specific Autoimmune Disease. *J. Proteomics* 230, 103989. doi:10.1016/j.jpro.2020.103989
- Wiśniewski, J. R., Zougman, A., Nagaraj, N., and Mann, M. (2009). Universal Sample Preparation Method for Proteome Analysis. *Nat. Methods* 6 (5), 359–362. doi:10.1038/nmeth.1322
- Wooff, Y., Man, S. M., Aggio-Bruce, R., Natoli, R., and Fernando, N. (2019). IL-1 Family Members Mediate Cell Death, Inflammation and Angiogenesis in Retinal Degenerative Diseases. *Front. Immunol.* 10, 1618. doi:10.3389/fimmu.2019.01618
- Wu, H., Hwang, D. K., Song, X., and Tao, Y. (2017). Association between Aqueous Cytokines and Diabetic Retinopathy Stage. *J. Ophthalmol.* 2017, 9402198. doi:10.1155/2017/9402198
- Yamagami, S., Yokoo, S., Mimura, T., and Amano, S. (2004). Effects of TGF-Beta2 on Immune Response-Related Gene Expression Profiles in the Human Corneal Endothelium. *Invest. Ophthalmol. Vis. Sci.* 45 (2), 515–521. doi:10.1167/iovs.03-0912
- Yao, Y., Li, R., Du, J., Long, L., Li, X., and Luo, N. (2019). Interleukin-6 and Diabetic Retinopathy: A Systematic Review and Meta-Analysis. *Curr. Eye Res.* 44 (5), 564–574. doi:10.1080/02713683.2019.1570274
- Yaswen, L., Kulkarni, A. B., Fredrickson, T., Mittleman, B., Schiffman, R., Payne, S., et al. (1996). Autoimmune Manifestations in the Transforming Growth Factor-Beta 1 Knockout Mouse. *Blood* 87 (4), 1439–1445. doi:10.1182/blood.v87.4.1439.bloodjournal8741439
- Yoshida, S., Sotozono, C., Ikeda, T., and Kinoshita, S. (2001). Interleukin-6 (IL-6) Production by Cytokine-Stimulated Human Müller Cells. *Curr. Eye Res.* 22 (5), 341–347. doi:10.1076/ceyr.22.5.341.5498
- Zeng, H. Y., Green, W. R., and Tso, M. O. (2008). Microglial Activation in Human Diabetic Retinopathy. *Arch. Ophthalmol.* 126 (2), 227–232. doi:10.1001/archophthol.2007.65
- Zhang, S., Zhang, S., Gong, W., Zhu, G., Wang, S., Wang, Y., et al. (2018). Müller Cell Regulated Microglial Activation and Migration in Rats with N-Methyl-N-Nitrosourea-Induced Retinal Degeneration. *Front. Neurosci.* 12, 890. doi:10.3389/fnins.2018.00890
- Zhang, S. X., Wang, J. J., Gao, G., Shao, C., Mott, R., and Ma, J. X. (2006). Pigment Epithelium-Derived Factor (PEDF) Is an Endogenous Antiinflammatory Factor. *FASEB J.* 20 (2), 323–325. doi:10.1096/fj.05-4313jfe

- Zhong, Y., Li, J., Chen, Y., Wang, J. J., Ratan, R., and Zhang, S. X. (2012). Activation of Endoplasmic Reticulum Stress by Hyperglycemia Is Essential for Müller Cell-Derived Inflammatory Cytokine Production in Diabetes. *Diabetes* 61 (2), 492–504. doi:10.2337/db11-0315
- Zode, G. S., Sethi, A., Brun-Zinkernagel, A. M., Chang, I. F., Clark, A. F., and Wordinger, R. J. (2011). Transforming Growth Factor-B2 Increases Extracellular Matrix Proteins in Optic Nerve Head Cells via Activation of the Smad Signaling Pathway. *Mol. Vis.* 17, 1745–1758.

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors, and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Schmalen, Lorenz, Grosche, Pauly, Deeg and Hauck. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.